This drugmaker's lead candidate could become a top-selling cancer therapy.
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Although death rates for some cancers are declining, the world is facing a sharp increase in cancer...
These relatively small companies are developing new cancer therapies that could generate billions in annual sales.
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQ:TIL) (“Instil” or the “Company”). The investigations concern...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (“Instil Bio” or the “Company”) (NASDAQ: TIL) on behalf...
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Instil Bio, Inc. (“Instil Bio” or the “Company”)...